Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial
Xavier Bosch(Universitat de Barcelona), Montserrat Rovira(Humanitas University), Jose T. Ortiz‐Pérez(Hospital Quirón Teknon), Rosario J. Perea(Hospital Clínic de Barcelona), Mariano Monzó(Hospital de León), Jordi Esteve(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Manuel Morales‐Ruiz(Universitat de Barcelona), Ariadna Domènech(Hospital Clínic de Barcelona), Teresa M. de Caralt(European Molecular Biology Laboratory), Marta Sitges(Hospital Clínic de Barcelona)
Cited by 28
Related Papers
The ‘Digital Twin’ to enable the vision of precision cardiology
|European Heart Journal|2020|811
Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies
|Journal of the American College of Cardiology|2013|631
Pulmonary Sarcoidosis: Typical and Atypical Manifestations at High-Resolution CT with Pathologic Correlation
|Radiographics|2010|490